Article
Author(s):
Even after the tremendous victory won by the American Lithotripsy Society and the Urology Society of America last year in federal court, urologists still must be concerned with Stark II and the federal anti-kickback statute.
FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
Pivotal trial launches of 64Cu-SAR-bisPSMA in BCR of prostate cancer
Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
Experts share insights on next-generation NMIBC therapies
Study shows value of precision-based approaches in prostate cancer